Journal of International Oncology

Journal of International Oncology››2013,Vol. 40››Issue (5): 345-347.

Previous ArticlesNext Articles

Pasireotidein tumor diagnosis and treatment by translational medicine

ZHU Hua, ZHOU Ni-Na, WANG Feng, YANG Zhi

  1. Department of Nuclear Medicine, Beijing Cancer Hospital & Beijing Institute for Cancer Research, Key Laboratory of Carcinogenesis and Translational Research, Ministry of Education, Beijing 100142, China
  • Online:2013-05-08Published:2013-05-15
  • Contact:YANG Zhi E-mail:pekyz@163.com

PDF

1233

Abstract:The somatostatin analogue pasireotide is a new type of protein which is the first therapeutic agent targeted to the pituitary. Pasireotide can prevent adrenocorticotropic hormone release and inhibit the growth of tumor cells after coupling with somatostatin receptor of the target cell membranes. Pasireotide have a high binding affinity for most of somatostatin receptor (SSTR) subtypes and in particular for SSTR5. Pasireotide can paly an important role in the new round of new targets for individualized diagnosis and treatment of tumor through the studies of translational medicine.

Key words:Receptors, somatostatin,Nuclear medicine,Translationsl medicine,Pasireotide